Fig. 2From: Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trialPD-L1 protein expression in cases with pathologic complete response (pCR) and residual disease (RD), and in pre- and post-treatment samples. a PD-L1 expression changes on tumor cells in cases with pCR (Wilcoxon test p = 0.435). b PD-L1 expression changes on tumor cells in cases with RD (Wilcoxon test p = 0.502). Pre- and post-treatment samples from the same patient are connected with lines. c PD-L1 expression comparisons between pCR and RD cases for all baseline samples (Wilcoxon test p = 0.1578). Shape and color of each dot represent treatment arm and ER status. d-f Similar figures as a-c showing changes and PD-L1 changes in stromal cells. Symbols ae the same as on Fig. 1Back to article page